Glenmark Pharma gets EIR for Goa facility from US FDA
· Business Standard Mkts
Glenmark Pharmaceuticals said that it has received the establishment inspection report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its formulations manufacturing facility in Goa, India.
The analysis
This is an USFDA action event. US regulatory status gates the export revenue that drives most Indian pharma earnings. A clearance reopens filings from that site; an alert freezes them, and the impact lands over quarters rather than days.
Market context
- Sector exposure: Pharma & Healthcare.
In this story
Related coverage
Stock Market Crash LIVE: Sensex Tanks Over 1,200 Points, Nifty 50 Below 22,200; ITC, JSW Steel, IndiGo Among Top Losers
INR vs USD: Rupee near 97/dollar; how TCS, Sun Pharma, Tata Steel, SRF may gain from weaker currency? Experts explain
Pharma stocks to buy ahead of Q2 results: Acutaas Chemicals, Mankind Pharma, Ipca Labs - Max upside? Target price
Sun Pharma to consider ₹15,000 crore NCD issue; board meeting on 12 October
Valiant Organics among 5 commodity stocks that hit 52-week highs and rallied up to 48% in a month